Evaluation of natalizumab pharmacokinetics and pharmacodynamics with standard and extended interval dosing

Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy

Gary Bloomgren, Sandra Richman, Christophe Hotermans et al. · New England Journal of Medicine · 2012 · 1.2K citations · Full text

Life Sciences, Neurology, Pharmacotherapy +17

Anti–JC virus antibody levels in serum or plasma further define risk of natalizumab‐associated progressive multifocal leukoencephalopathy

Tatiana Plavina, Meena Subramanyam, Gary Bloomgren et al. · Annals of Neurology · 2014 · 438 citations · Full text

Life Sciences, Immunology, Infectious Diseases +15

The incidence and significance of anti-natalizumab antibodies

Peter A. Calabresi, Gavin Giovannoni, Christian Confavreux et al. · Neurology · 2007 · 333 citations

Pharmacy, Immunology, Neurology +17

Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies

Pei‐Ran Ho, Harold Koendgen, Nolan Campbell et al. · The Lancet Neurology · 2017 · 322 citations

Life Sciences, Neurology, Neuroscience +14

Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function

Bhupendra Khatri, S. Man, Gavin Giovannoni et al. · Neurology · 2009 · 280 citations · Full text

Life Sciences, Immunology, Pharmacology +17